

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Boehringer Ingelheim Animal Health USA Inc.
USDA Vet Biologics Establishment Number	124
Product Code	16D1.21
True Name	Feline Rhinotracheitis-Calici-Panleukopenia Vaccine, Modified Live Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Solo-Jec Feline 3 - No distributor specified
Date of Compilation Summary	October 21, 2019

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

124 16D1.21 Page 1 of 15

Study Type	Efficacy
Pertaining to	Feline Calicivirus (FCV)
Study Purpose	To demonstrate effectiveness against respiratory disease due to Feline Calicivirus
Product Administration	Two doses administered 21 days apart subcutaneously (SC)
Study Animals	Thirty three (33) cats, 8 weeks of age. Cat were randomized
	into one vaccinated group of 23 cats and one group of 10 non-vaccinated controls.
Challenge Description	31 days post second vaccination all cats were challenged with FCV.
Interval observed after	Rectal temperatures and clinical signs were observed daily for 14
challenge	days post challenge.
Results	Vaccinates and controls were evaluated per the criteria in 9 CFR 113.314(c)(3)
	A significant difference in clinical signs was observed between vaccinates and controls using a scoring system approved by APHIS.
	Requirements of 113.314(c)(3) were met.
	See the next page for data.
USDA Approval Date	November 4, 1998

124 16D1.21 Page 2 of 15

FCV Post challenge Daily Clinical Signs

	14DPC	2	2		2			1		1		1		1		1	2	2	2	1				1
	13DPC	2	2		2			П		1	1	1		1		1	2	2	2	2				1
	12DPC	2	2		2			2		1	3	1,5		1		1	2	2	2	2				1
	11DPC	2	2		2			2		1	3	2,5		1		1	2	2	2	2				2
	10DPC	2	2		2			2		1	3	2,5		1		1	2	2	2	2				2
	9DPC	2	2	1	2			2		1	3,2	1,2,5		1	1	1	2	2	2	2				1,2
	8DPC	2	2	1	2			2		1	3,2	1,2,5		1	3,6	1	2	2	2	2				1,2
Vaccinates	7DPC	2	2	1	2			2	1		3,2	1,2,5		1		1	2	2	2	2				1,2
Va	6DPC	2	2	1	2			2	1		3,2	1,2,5		1		1	2	2	2	2			2	1,2
	5DPC	2	2	1	2			2			3,2	1,2,5		1		1	2	2	2	2			2	1,2
	4DPC	1	2		2			2				1,2,5		1	5		2	1	2	1			5	2
	3DPC				3			2									2	1	2				5	
	2DPC																							
	1DPC																							
	0DPC																							
	Cat	1	2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	22	23

No entry=no signs noted

9 - snuffing

5- External Non-bleeding ulcer(s)

6- External bleeding ulcer(s) 7- Anorexia

8- Dehydration

3- Multiple oral ulcers <4mm 4- Multiple oral ulcers >4mm

1- One oral ulcer <4mm2- One oral ulcer >4mm

10 - coughing11 - mouth breathing12 - Depression

DPC – days post-challenge

124 16D1.21 Page 3 of 15

FCV Post challenge Daily Clinical Signs

						N	Non-Vaccinated Controls	inated	Control	S					
Cat	0DPC	1DPC	1DPC 2DPC 3DPC	3DPC	4DPC	5DPC	6DPC	7DPC	8DPC	5DPC 6DPC 7DPC 8DPC 9DPC	10DPC	11DPC	11DPC 12DPC 13DPC 14DPC	13DPC	14DPC
1							2	2	5	5	5				
2				1	1	1,2,6	1,2,6	1,2,6	2,6	2,6	2,6	2,6	2,6	2,6	2,6
3					2	4	4	4	4	4	8				
4				1	2	2	2	1,2	1,2	1,2	1,2	3,2	3,2	3,2	2
5				2	2	2	2	2	2	2	2	2	2	2	2
9				3,2	2	2	7	2	2	2	2	2	2	2	2
7										1	1	1	1	1	1
8						4,6	4,6	4,6	4,6	4,6	4,6	4,6	1,2,5	1,2,5	1,2,5
6					2	2	2	1,2	1,2	1,2	2	2	7	2	2
10						3	3	4	4	4	4	1,2	1,2	1,2	3

No entry=no signs noted		gu	
9 - snuffing	10 - coughing	11- mouth breathing	12 - Depression
5- External Non-bleeding ulcer(s)	6- External bleeding ulcer(s)	7- Anorexia	8- Dehydration
1- One oral ulcer <4mm	2- One oral ulcer >4mm	3- Multiple oral ulcers <4mm	4- Multiple oral ulcers >4mm

DPC – days post-challenge

FCV Post challenge Daily Body Temperature (°F)

							Vac	Vaccinates	S						
Cat	0DPC	1DPC	2DPC	ЗДРС	4DPC	5DPC	OPC	7DPC	8DPC	9DPC	10DPC	11DPC	12DPC	13DPC	14DPC
1	101.9	102.4	101.9	102.2	102.1	102.4	101.3	101.4	101.6	101.5	101.2	101.1	101.1	101.1	101.3
2	101.7	101.6	101.9	102.1	103.1	101.4	101.8	101.0	101.8	101.4	101.7	101.4	101.7	101.3	101.8
3	101.2	102.1	101.8	102.7	101.5	101.8	101.2	101.0	101.4	101.1	101.0	101.1	101.4	101.0	101.7
4	101.8	102.6	101.7	102.6	101.9	102.0	102.0	101.5	101.2	101.8	101.7	101.7	101.2	101.8	101.7
2	100.8	101.0	100.8	101.6	101.5	101.4	101.4	101.9	101.7	101.5	101.1	101.3	101.1	101.4	101.4
9	101.7	102.1	101.3	101.1	101.3	101.1	101.5	101.0	101.4	101.7	101.2	101.5	101.0	101.2	101.6
7	101.2	103.2	101.5	102.6	101.9	101.5	101.5	101.0	101.5	101.4	101.9	101.9	101.9	101.3	101.9
8	101.6	101.7	101.6	101.9	101.7	101.9	101.5	101.7	101.5	101.5	101.5	101.6	101.2	101.5	101.0
6	101.5	102.1	101.7	101.9	102.0	101.8	101.2	101.6	101.6	101.1	101.8	101.6	101.7	101.1	101.1
10	101.3	103.1	102.1	102.1	102.1	101.7	101.8	101.0	101.4	101.4	101.4	101.5	101.1	101.0	101.8
11	100.3	102.2	102.1	103.0	102.9	102.1	102.0	101.0	101.5	101.6	101.9	101.4	101.0	101.0	101.2
12	102.3	103.0	102.4	101.6	101.7	103.1	101.8	102.2	101.8	101.4	101.7	101.9	101.9	101.3	101.1
13	101.2	101.4	101.2	101.7	101.2	101.8	101.7	101.4	101.8	101.1	101.4	101.4	101.5	101.4	101.5
14	100.4	102.3	101.8	101.2	101.7	101.9	101.5	101.3	101.8	101.9	101.1	101.1	101.7	101.6	101.5
15	101.6	102.1	102.4	102.0	101.6	101.6	101.2	101.2	102.3	101.5	101.2	101.0	101.6	101.0	101.0
16	100.9	102.1	103.7	103.4	102.9	102.5	102.3	101.8	101.4	101.6	101.3	101.2	101.2	101.0	101.1
17	101.5	102.8	101.8	102.4	102.6	102.1	101.1	101.8	101.6	101.9	102.0	101.9	101.4	101.4	102.0
18	101.0	102.0	101.1	103.4		101.1	101.0	101.0	101.1	101.2	101.2	101.3	101.7	101.3	101.6
19	100.8	102.5	101.4	101.0	102.1	101.5	101.8	101.3	101.1	101.8	101.4	101.4	101.3	101.1	101.0
20	100.5	101.7	101.7	101.4	102.0	101.0	101.6	101.3	101.2	101.1	101.1	101.4	101.7	101.1	101.0
21	101.9	102.4	102.0	101.8	101.8	101.9	101.1	101.5	101.8	101.8	102.0	102.1	101.1	101.2	101.6
22	100.4	101.7	102.1	102.0	102.0	101.2	101.6	101.4	102.0	101.3	101.9	101.4	101.1	101.1	101.0
23	101.0	102.7	102.6	102.8	101.4	102.3	101.6	101.3	101.4	101.0	101.3	101.6	101.5	101.6	101.2

DPC – days post-challenge

124 16D1.21 Page 5 of 15

FCV Post challenge Daily Body Temperature (°F)

						N	Non-Vaccinated Controls	nated (Control	5					
Cat	0DPC	0DPC 1DPC 2DPC 3DPC	2DPC	3DPC	4DPC	5DPC	5DPC 6DPC	7DPC	8DPC	9DPC	10DPC		11DPC 12DPC	13DPC	14DPC
1	100.3	102.1	101.7	101.5	102.1	102.4	102.4	101.7	102.0	101.0	101.4	101.0	101.0	101.6	101.3
2	101.0	101.7	101.4	102.2	102.9	102.1	101.6	101.3	101.5	101.3	101.1	101.4	101.4	101.5	101.1
3	102.0	102.8	101.9	102.3	101.8	101.3	101.2	101.3	101.4	101.7	101.9	101.4	101.0	101.6	101.2
4	102.7	102.7	102.4	102.8	102.8	101.5	101.2	101.8	101.3	101.2	101.1	101.7	101.6	101.2	101.4
2	101.7	102.1	102.1	103.6	102.3	102.7	102.1	102.2	102.0	101.1	101.2	101.1	101.6	101.0	101.7
9	101.0	102.0	101.4	104.0	103.0	103.1	102.7	101.0	101.0	101.3	101.0	101.0	101.0	101.3	101.7
7	101.1	102.6	101.3	101.4	102.0	102.3	101.4	101.3	101.1	101.6	101.5	101.6	101.8	101.9	101.2
8	102.0	102.5	102.1	101.6	101.1	102.4	101.6	101.7	101.7	102.1	101.2	101.5	101.6	101.3	101.6
6	102.1	102.2	102.0	102.4	103.2	103.2	102.1	102.3	101.6	101.6	101.5	101.7	101.2	101.1	101.0
10	102.7	102.4	103.7	104.6	103.9	102.9	101.3	102.5	101.9	101.8	101.7	101.1	101.2	101.2	101.3

DPC – days post-challenge

124 16D1.21 Page 6 of 15

Study Type	Efficacy
Pertaining to	Feline Viral Rhinotracheitis (FVR)
Study Purpose	To demonstrate effectiveness against FVR
Product Administration	Two doses administered 21 days apart subcutaneously (SC)
Study Animals	Forty-two (42) cats, 8 weeks of age. Cats were randomized
	into two vaccinated groups of 22 and 10 cats, respectively,
	and one group of 10 non-vaccinated controls.
Challenge Description	21 days post second vaccination all cats were challenged with FVR virus.
Interval observed after	Rectal temperatures and clinical signs were observed daily for 14
challenge	days post challenge.
Results	Vaccinates and controls were evaluated per the criteria in 9 CFR 113.315(c)(3) A significant difference in clinical signs was observed between vaccinates and controls using a scoring system approved by APHIS.
	Requirements of 113.315(c)(3) were met. See the next page for data.
USDA Approval Date	July 1, 1999

124 16D1.21 Page 7 of 15

14DPC NSM,AN MM M NSM NSM NSM NSM NSM NSM AN Empty=no signs observed SN, NSM, AN SN,NSM SN,NSM 13DPC SN,NSM NSM NSM NSM S SN SN S S S SN,OMM,NMM,AN SN,OMM,NSM NSM,AN OSM, NSM SN,NSM SN,NSM 12DPC NSM NSM NSM OSM NSM NSM SN,OMM,NMM,AN CO-Coughing BR-Open Mouth Breathing OSM, NSM, AN 11DPC SN,NSM OSM, NSM NSM,AN NSM SN,OSD,NSD,AN SN,OSM,NSM,AN OSM,NMM NSM,AN NSM,AN NSM,AN SN,NSM 10DPC NSM NSM NSM NSM NSM NSM NSM S S SN, DH, OSM, NSM, AN FVR Post challenge Daily Clinical Signs OSM, NMM, AN NSM,AN SN,NSM NSM,AN NSM,AN SN,NSM SN,OSM SN-Sneezing 9DPC NSM NSM NSM NSM S S AN Group 1 OMM,NMM,AN OSM, NMM, AN OSM,NSM NSM,AN OSM, NSM SN,NSM SN,AN Vaccinates -SDPC NSM OSM NSM NSM NSM NSM AN Ā AN Ā Nasal Discharge SN,OSM,NSM,AN OSM, NSM, AN OSM, NSM, AN SN,NSM,AN SN,OSM,NSM SN,NSM,AN SN,NSM,AN OSM,NSM SN,NSM SN,OSM SN,NSM 7DPC NSM NSM OSM NSM S OSM S S SN,OSM,AN SN, DH, AN SN, DH, AN 6DPC SN,DY SN, DY SN OSM S OSM ŏ OSM OSM Ā SS AN Ocular Discharge DH, NSM, AN D,DH,NSM SN,DH,AN OSM,NSM SN,OSM SN,OSM SDPC OSM OSIM AN 품 AN OSM, NSM р, рн, ру SN, DY SN,AN 4DPC OSM S S S 3DPC SN Ω SN S S 2DPC IDPC Ω ODPC А 15 7 4 s φ 7 00 σ 9 11 12 13 14 16 17 18 13 20 21 22 m Ę,

D-Depression

AN-Anorexia DH-Dehydration I

DY-Snuffing

NMM-Mild Mucoid NMD-Moderate Mucoid

OMM-Mild Mucoid OMD-Moderate Mucoid

OSD-Moderate serous OSM-Mild serous

NSD-Moderate Serous

NSM - Mild Serous

DPC – Days post-challenge

124 16D1.21 Page 8 of 15

NSM,AN NSM,AN 14DPC 14DPC MM NSM AN AN AN SN,OMM,NMM,AN SN,NSM,AN 13DPC SN,NSM SN,NSM SN,NSM SN,NSM 13DPC NSM NSM SN S S S S S S OMM, NMM, AN OSM,AN NSM,AN SN,NSM SN,OSM SN,NSM 12DPC SN,NSM 12DPC SN,OSM NSM MSM NSM NSM NSM SN S SN OMM,NMM,AN OSM,NSM,AN OSM,NSM SN,NSM OMM,AN NSM,AN NMM,AN 11DPC 11DPC OSM NSM OSM NSM NSM OSM S SN SN SN,OMM,NMM,AN OSM,NSM,AN OSM,NSM SN,NSM NSM SN,OSM NMM,AN SN,OSM OMM,AN SN,NSM SN,OSM SN,OSM 10DPC 10DPC SN,AN SN, AN NSM OSM AN DH,OMM,NMM,AN SN,OSM,NSM,AN SN,OSM,NSM,AN **FVR Post challenge Daily Clinical Signs** SN,OSM,NSM SN,OSM,NSM SN,OSM,AN SN, NSM, AN NSM,AN SN,NSM NSM.AN SN,NMM SN,NSM SN,OSM NMM,AN 9DPC MMN 9DPC NSM NSM S OSM Non-Vaccinated Controls SN,D,DY,OSM,AN DY,OSM,NSM,AN OSM, NMM, AN OSM, NSM, AN SN,OSM,NSM OSM,NSM,AN SN,OSM,AN NSM,AN SN,NSM SN,NSM OSM,AN DY,NSM SN,NSM SN,NSM SDPC SDPC Vaccinates -NSM NSM NSM NSM SN,OSM,NSM,AN SN,OSM,NSM,AN SN,OSM,NSM SN,OSM,NSM SN,OSM,NSM SN,OSM,NSM SN,NSM,AN NSM,AN SN,NSM SN,NSM NSM,AN SN,OSM SN,AN 7DPC 7DPC OSM NSM OSM S SN S SN,OSM,AN SN,OSM SN,OSM 6DPC 6DPC SN,AN NSM NSM OSM OSM OSM S S S S SN,OSM,BR,AN SN,OSM,AN SN,OSM,BR SN,D,OSM DH,OSM SN,OSM SN,OSM SN,NSM SDPC OSM SDPC OSM OSM OSM SN Ā SN,CO,OSM DY,OSM SN,OSM SN,OSM SN,OSM 4DPC SN,DY 4DPC SN,CO OSM OSM S SN ò 3DPC 3DPC S S S S S 2DPC 2DPC IDPC IDPC Ā ODPC ODPC Cat ID C. Et 9 ø 10 4 ø 7 σ 7 m 4 S 7 oo o

Ocular Discharge	Nasal Discharge	SN-Sneezing CO-Coughing	CO-Coughing	Empty=no signs observed
OSM-Mild serous	NSM - Mild Serous	AN-Anorexia	BR-Open Mouth Breathing	
OSD-Moderate serous	NSD-Moderate Serous	DH-Dehydration D-Depression	D-Depression	
OMM-Mild Mucoid	NNIM-Mild Mucoid	DY-Snuffing		
OMD-Moderate Mucoid	OMD-Moderate Mucoid NMD-Moderate Mucoid			

DPC – Days post-challenge

124 16D1.21 Page 9 of 15

FVR Post challenge Daily Body Temperature (°F)

	14DPC	100.0	101.0	101.2	101.9	101.0	101.3	100.9	102.0	100.5	100.3	100.7	101.4	101.0	101.7	100.4	101.1	100.3	100.8	101.9	101.3	6.66	100.2
	13DPC	101.7	101.3	100.7	101.7	102.2	101.9	102.1	101.7	100.7	101.7	101.2	101.7	101.4	101.5	101.0	101.1	100.0	100.1	102.3	101.3	100.7	101.4
	12DPC	101.5	101.7	100.6	102.1	101.2	102.3	101.9	100.8	101.2	101.2	101.3	101.8	101.0	101.8	100.9	101.7	101.4	101.4	102.1	102.2	100.7	101.3
	11DPC	101.5	101.1	101.2	101.1	102.1	101.7	100.9	101.5	100.0	101.8	101.5	101.8	101.0	100.9	101.4	102.3	100.6	101.1	101.9	102.4	100.8	100.5
	10DPC	101.2	101.7	101.4	102.0	102.2	102.0	102.4	101.2	100.6	101.7	100.4	101.7	101.2	102.2	100.8	101.5	101.0	101.5	102.6	103.1	101.4	101.1
	9DPC	101.4	101.1	100.5	102.3	102.4	101.5	101.4	100.0	6.66	101.5	100.6	101.4	100.7	100.8	100.1	101.3	100.9	101.3	102.6	102.4	101.7	101.2
-	8DPC	100.3	101.4	100.0	102.4	102.5	100.7	101.4	100.4	100.0	101.2	100.7	101.3	101.3	100.7	100.6	101.7	101.1	101.3	102.5	102.5	102.5	101.2
S - Group 1	7DPC	101.1	101.5	101.1	102.3	101.5	101.2	102.4	100.3	100.4	100.7	101.7	101.2	100.1	100.9	100.8	101.7	100.8	101.2	102.8	102.4	102.2	101.9
Vaccinates -	6DPC	101.2	101.3	101.2	101.3	100.8	101.1	101.6	100.2	101.2	101.8	101.3	100.6	101.3	101.8	100.8	101.2	101.2	101.1	101.5	101.7	101.9	101.0
^	5DPC	101.6	101.3	103.6	101.2	102.9	101.4	102.3	100.6	101.4	101.5	101.0	101.8	100.8	102.2	102.0	102.8	101.9	100.4	103.1	102.1	101.8	101.2
	4DPC	103.4	104.7	101.4	101.5	100.5	104.7	101.7	103.4	104.6	104.4	103.8	101.9	100.8	101.3	101.3	101.8	102.9	102.1	103.8	101.8	104.1	103.3
	3DPC	100.0	100.9	100.3	100.6	100.8	101.0	100.4	100.8	101.3	101.1	101.3	100.0	1001	100.2	100.9	101.1	101.5	101.3	101.1	101.5	101.7	100.7
	2DPC	101.1	100.9	100.7	101.3	100.9	101.0	100.7	100.7	100.8	101.3	101.0	101.0	100.3	100.4	101.0	101.5	100.9	101.1	100.8	101.0	100.5	101.1
	1DPC	100.0	100.8	100.8	100.3	101.2	100.9	101.2	100.3	100.8	100.6	100.1	100.4	6.66	100.5	101.0	101.1	100.8	100.5	100.4	101.1	100.0	101.2
	0DPC	100.4	101.6	100.8	101.3	100.2	101.4	100.6	100.9	101.4	101.2	100.9	100.9	100.6	100.0	101.5	101.2	101.2	100.8	100.8	101.2	100.3	100.6
	Cat ID	1	2	3	4	5	9	7	8	6	10	11	12	13	14	15	16	17	18	19	20	21	22

DPC – Days post-challenge

124 16D1.21 Page 10 of 15

FVR Post challenge Daily Body Temperature (°F)

			_							_
14DPC	100.0	101.0	101.1	101.6	100.6	101.5	100.2	101.7	101.8	100.4
13DPC	101.5	100.7	102.5	102.7	100.8	100.6	100.4	101.8	101.6	100.8
12DPC	101.4	101.8	102.0	100.0	101.9	101.3	100.6	101.6	102.8	101.9
11DPC	101.2	101.5	102.5	101.9	101.6	101.1	100.6	102.6	102.6	101.5
10DPC	101.3	101.3	102.7	102.1	101.5	102.3	101.2	102.3	102.2	101.5
9DPC	101.6	101.1	102.2	101.9	101.6	101.3	101.0	101.4	102.6	101.3
8DPC	101.5	101.1	102.4	101.7	101.7	100.6	100.4	102.3	102.5	102.4
7DPC	100.7	101.2	102.0	101.9	101.7	102.2	101.2	102.5	102.1	102.6
6DPC	100.2	101.6	100.9	100.2	101.2	101.9	101.0	102.2	102.7	102.0
5DPC	101.3	101.2	101.8	101.5	101.4	102.7	102.2	101.7	103.2	101.9
4DPC	101.7	101.7	101.6	102.7	102.0	104.6	101.4	103.1	102.8	102.9
3DPC	100.7	100.7	101.9	100.4	100.3	100.7	100.7	101.1	100.5	102.5
2DPC	100.4	100.6	100.8	100.7	101.0	101.5	101.3	101.1	101.6	100.7
1DPC	101.1	101.0	101.4	100.2	100.1	100.9	1001	100.6	101.3	100.6
0DPC	100.0	100.8	100.6	100.9	100.4	101.7	100.7	100.7	101.8	100.6
Cat ID	1	2	3	4	5	9	7	8	6	10
	0DPC 1DPC 2DPC 4DPC 5DPC 7DPC 8DPC 9DPC 10DPC 11DPC 12DPC 13DPC	0DPC 1DPC 2DPC 3DPC 4DPC 5DPC 6DPC 7DPC 8DPC 9DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 101.5 101.5 101.5 101.3 101.4 101.5	0DPC 1DPC 2DPC 3DPC 4DPC 5DPC 4DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 3DPC 4DPC 5DPC 4DPC 7DPC 8DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 3DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 6DPC 7DPC 8DPC 4DPC 10DPC 10DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 100.5 100.1 100.1 101.3 101.2 101.4 100.1 101.4 100.1 101.4 100.1 100.7 100.1 100.1 100.1 100.7 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.1 100.0 100.7 100.7 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1</td><td>ODPC IDPC 2DPC 4DPC 5DPC 6DPC 7DPC 8DPC 4DPC 10DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 100.1 101.3 101.3 101.3 101.4 101.4 100.8 101.0 100.7 101.7 101.6 102.0 102.4 102.7 102.7 101.8 100.7 100.9 100.1 100.2 101.5 100.2 101.9 102.7 102.0 102.0 102.7 102.0 102.7 102.1 102.0 102.7 102.0 102.7 102.1 102.0 102.0 102.7 102.0 102.0 102.7 102.0 102.7 101.9 102.1 101.7 101.7 101.9 102.1 101.9 102.7 101.9 102.7 101.7 101.7 101.9 102.1 101.9 102.1 101.9 102.1 101.9 102.1 101.9 101.1 101.1 101.1 <</td><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""></th<></td></th<></td></th<></td></th<></td></th<></td></th<>	ODPC IDPC 2DPC 3DPC 4DPC 5DPC 4DPC 7DPC 8DPC 4DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 3DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 6DPC 7DPC 8DPC 4DPC 10DPC 10DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 100.5 100.1 100.1 101.3 101.2 101.4 100.1 101.4 100.1 101.4 100.1 100.7 100.1 100.1 100.1 100.7 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.1 100.0 100.7 100.7 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1</td><td>ODPC IDPC 2DPC 4DPC 5DPC 6DPC 7DPC 8DPC 4DPC 10DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 100.1 101.3 101.3 101.3 101.4 101.4 100.8 101.0 100.7 101.7 101.6 102.0 102.4 102.7 102.7 101.8 100.7 100.9 100.1 100.2 101.5 100.2 101.9 102.7 102.0 102.0 102.7 102.0 102.7 102.1 102.0 102.7 102.0 102.7 102.1 102.0 102.0 102.7 102.0 102.0 102.7 102.0 102.7 101.9 102.1 101.7 101.7 101.9 102.1 101.9 102.7 101.9 102.7 101.7 101.7 101.9 102.1 101.9 102.1 101.9 102.1 101.9 102.1 101.9 101.1 101.1 101.1 <</td><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""></th<></td></th<></td></th<></td></th<></td></th<>	ODPC IDPC 2DPC 3DPC 4DPC 5DPC 4DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 6DPC 7DPC 8DPC 4DPC 10DPC 10DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 100.5 100.1 100.1 101.3 101.2 101.4 100.1 101.4 100.1 101.4 100.1 100.7 100.1 100.1 100.1 100.7 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.1 100.0 100.7 100.7 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1</td><td>ODPC IDPC 2DPC 4DPC 5DPC 6DPC 7DPC 8DPC 4DPC 10DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 100.1 101.3 101.3 101.3 101.4 101.4 100.8 101.0 100.7 101.7 101.6 102.0 102.4 102.7 102.7 101.8 100.7 100.9 100.1 100.2 101.5 100.2 101.9 102.7 102.0 102.0 102.7 102.0 102.7 102.1 102.0 102.7 102.0 102.7 102.1 102.0 102.0 102.7 102.0 102.0 102.7 102.0 102.7 101.9 102.1 101.7 101.7 101.9 102.1 101.9 102.7 101.9 102.7 101.7 101.7 101.9 102.1 101.9 102.1 101.9 102.1 101.9 102.1 101.9 101.1 101.1 101.1 <</td><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""></th<></td></th<></td></th<></td></th<>	ODPC IDPC 2DPC 4DPC 5DPC 6DPC 7DPC 8DPC 4DPC 10DPC 10DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 100.5 100.1 100.1 101.3 101.2 101.4 100.1 101.4 100.1 101.4 100.1 100.7 100.1 100.1 100.1 100.7 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.2 100.7 100.1 100.0 100.7 100.7 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1 100.1	ODPC IDPC 2DPC 4DPC 5DPC 6DPC 7DPC 8DPC 4DPC 10DPC 10DPC 11DPC 12DPC 13DPC 100.0 101.1 100.4 100.7 101.3 100.1 101.3 101.3 101.3 101.4 101.4 100.8 101.0 100.7 101.7 101.6 102.0 102.4 102.7 102.7 101.8 100.7 100.9 100.1 100.2 101.5 100.2 101.9 102.7 102.0 102.0 102.7 102.0 102.7 102.1 102.0 102.7 102.0 102.7 102.1 102.0 102.0 102.7 102.0 102.0 102.7 102.0 102.7 101.9 102.1 101.7 101.7 101.9 102.1 101.9 102.7 101.9 102.7 101.7 101.7 101.9 102.1 101.9 102.1 101.9 102.1 101.9 102.1 101.9 101.1 101.1 101.1 <	ODPC IDPC 2DPC 4DPC 5DPC 4DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""></th<></td></th<></td></th<>	ODPC IDPC 2DPC 4DPC 5DPC 4DPC 4DPC <th< td=""><td>ODPC IDPC 2DPC 4DPC 5DPC 4DPC <th< td=""></th<></td></th<>	ODPC IDPC 2DPC 4DPC 5DPC 4DPC 4DPC <th< td=""></th<>

						_	Non-Vaccinated Controls	cinated (Controls						
Cat ID	0DPC	1DPC	2DPC	3DPC	4DPC	5DPC	6DPC	7DPC	8DPC	9DPC	10DPC	11DPC	12DPC	13DPC	14DPC
1	100.7	101.1	101.2	100.4	102.0	105.0	102.0	105.0	101.4	102.2	101.3	101.7	101.8	100.0	100.8
2	101.0	100.3	101.1	100.6	101.4	103.3	101.2	102.3	103.2	101.8	102.5	102.5	101.2	102.2	100.0
3	101.3	101.5	102.0	101.2	101.6	105.3	101.2	101.8	103.5	103.5	101.6	100.5	101.3	101.9	101.7
4	101.5	100.7	101.3	101.2	103.6	101.7	104.0	102.0	102.7	101.1	101.1	101.6	101.4	101.2	101.1
2	102.1	101.4	101.7	101.4	102.1	103.5	101.0	104.7	101.5	102.6	101.4	101.4	102.4	100.8	100.6
9	101.6	101.3	101.3	100.5	103.0	101.8	102.6	103.6	103.4	100.7	101.7	101.0	102.2	100.5	101.0
7	101.3	100.4	101.2	100.9	104.6	101.3	102.8	102.0	103.0	100.5	101.3	101.8	101.7	100.0	100.5
8	101.1	100.3	101.4	100.7	103.7	102.5	103.9	102.4	102.4	101.2	101.4	101.9	101.8	100.6	101.7
6	100.5	100.0	100.9	100.0	102.0	100.9	101.2	105.5	101.8	102.3	102.4	101.5	101.4	101.1	100.0
10	101.5	101.4	101.6	101.1	103.8	102.2	104.3	102.2	102.0	100.6	101.4	100.8	100.7	100.9	100.0

DPC – Days post-challenge

124 16D1.21 Page 11 of 15

Study Type	Efficacy						
Pertaining to	Feline Panleukopenia Virus (FPV)						
Study Purpose	To demonstrate effectiveness against FPV						
Product Administration	Two doses administered 21 days apart subcutaneously (SC)						
Study Animals	Thirty-three (33) cats 8 weeks of age. Cats were randomized						
	into one vaccinated group of 23 cats and one group of 10 non-vaccinated controls.						
Challenge Description	85 days post second vaccination all cats were challenged with virulent FPV.						
Interval observed after	Rectal temperatures and clinical signs were observed daily for 14						
challenge	days post challenge.						
Results	Vaccinates and controls were evaluated for leukopenia (defined as ≥ 50% decrease in white blood cells from pre-challenge levels). Positive for Leukopenia: Vaccinates: 0/0 (0%) positive Controls: 9/10 (90%) positive See the next page for data.						
USDA Approval Date	June 30, 1999						

124 16D1.21 Page 12 of 15

White Blood Cell Counts (counts/uL blood) Following FPV Challenge Non-Vaccinated Controls

Cat ID	Baseline Avg.	2DPC	4DPC	6DPC 8DPC		10DPC	
1	18938	10890	8800	8360	7425	7810	
2	11713	9405	6930	4125	5280	7865	
3	3 12962 9735 4656 561		5610	3685	6325		
4	11110	11000	4290	3630	4840	4510	
5	12907	6105	4730	5555	6490	5005	
6	15345	11440	3905	5280	9625	7425	
7	14630	11550	5170	7095	7535	7920	
8	13182	10945	5253	4565	8855	10340	
9	12173	9240	7480	7810	8580	10120	
10	12760	9405	8250	6050	15510	12045	

Vaccinates							
Cat ID	Baseline Avg.	2DPC	4DPC	6DPC 8DPC		10DPC	
11	14777 12155		21725	19305	20845	18040	
12	12888	12650	9295	13090	13970	13475	
13	11293	9955	11825	14410	12375	10505	
14	14 10102 9955		10945 11275		12980	10725	
15	8855	7590	8250	11550	11165	9295	
16	13475	11165	11495	10120	10890	13365	
17	10560	7755	15180	10450	13090	10505	
18	17600	16354	18755	23650	18810	13255	
19	16262	13145	14190	15785	16500	15950	
20	12797	9625	12375	16280	15345	11825	
21	14758	11660	12430	11770	11660	12430	
22	14080	10560	10285	13145	17765	20570	
23	10908	8690	7370	9900	11935	7810	
24	13548	3548 10010 11770 15685		15685	12870	12760	
25	13237	10395	11495	13585	18700	10505	
26	13640	12320	14080	16225	15840	13860	
27	13182	10615	12925	12650	16885	11303	
28	10102	8140	8525	9405	12595	11880	
29	11807	9570	17160	14350	11770	14465	
30	13787	9625	17050	13255	14740	11743	
31	13732	12870	17160	15180	15620	10780	
32	10835	9515	15840	8305	11220	9900	
33	12357	8414	17380	10065	11055	10450	

DPC = Days Post Challenge

124 16D1.21 Page 13 of 15

Study Type	Safety							
Pertaining to	All fractions							
Study Purpose	Demonstrate safety of product under typical use conditions							
Product Administration	Either one or two doses of vaccine was administered 3 - 4							
	weeks apart by the subcutaneous route. A total of 1386 doses							
	were administered.							
Study Animals	A total of 716 cats, 282 eight weeks of age or younger and 434							
	greater than 8 weeks, received vaccine. Cats were privately							
	owned and from commercial catteries.							
Challenge Description	Not applicable							
Interval observed after	No challenge. Cats were observed for 30 minutes after							
challenge	vaccination and then daily for 2 weeks after each vaccination.							
Results	Frequency of adverse events is summarized on the next page.							
HCD A A LD :	0-4-120 1000							
USDA Approval Date	October 29, 1998							

124 16D1.21 Page 14 of 15

Summary of Reactions:

	up to 8 weeks of age				> 8 Weeks of Age					
Reaction Type	<24h	>24h	Total by dose	%	<24h	>24h	Total by dose	%	Sum of Doses	Percent
None	NA	NA	543	98.7%	NA	NA	785	93.4%	1328	95.82%
Fever	0	0	0	0.00%	2	0	2	0.24%	2	0.14%
Lethargy	3	0	3	0.55%	14	0	14	1.67%	17	1.23%
Vomiting	1	0	1	0.18%	2	0	2	0.24%	3	0.22%
Diarrhea	0	0	0	0.00%	2	0	2	0.24%	2	0.14%
Injection Site Soreness	4	0	4	0.73%	0	0	0	0.00%	4	0.29%
Anorexia									1	0.08%
Eye problem									5	0.38%
Lost to follow- up									10	0.72%
Unrelated Mortality*									14	1.06%
Total Doses			550				836		1386	

^{*}Affirmed by licensee to have a non-vaccine cause.

124 16D1.21 Page 15 of 15